PDCD1 and melanoma: At present, relatlimab is the most developed anti-LAG-3 antibody, and a randomized double-blind phase II/III trial (NCT03470922) is currently investigating its effectiveness in combination with anti-PD-1 antibodies, principally nivolumab, in several tumor models, including melanoma [93].